Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DS41PJ
|
|||
| Drug Name |
ARV-471
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65; ICD-10: C50, C79.51] | Phase 1/2 | [1] | |
| Company |
Arvinas
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04072952) A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (mBC). U.S. National Institutes of Health. | |||
| REF 2 | Targeting estrogen receptor alpha for degradation with PROTACs: A promising approach to overcome endocrine resistance. Eur J Med Chem. 2020 Nov 15;206:112689. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.